Trop2-expression in primary vulvar squamous cell carcinoma
The ubiquitous expression of Trop2 makes it an interesting potential target for the Trop2 directed antibody drug conjugate (ADC) sacituzumab govitecan (SG). Clinical trials evaluating the safety and effectiveness of SG in VSCC are needed.
Authors
- Nelson John
- Arndt Hartmann (ORCID: https://orcid.org/0000-0002-4860-4626)
- Christian Matek (ORCID: https://orcid.org/0000-0001-8528-8581)
- Lothar Häberle
- Antje Knöll (ORCID: https://orcid.org/0000-0002-1294-6923)
- Ramona Erber (ORCID: https://orcid.org/0000-0003-0315-1229)
- Matthias W. Beckmann
- Frederik A. Stuebs
- Carol I. Geppert
- Carlos Bercebal
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University Hospital Regensburg (DE)
- Comprehensive Cancer Center Erlangen (DE)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1016/j.ygyno.2025.03.049
- Citations
- 3
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Friedrich-Alexander-Universität Erlangen-Nürnberg
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg